Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As2O3) on myeloma cells
Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As2O3) on myeloma cells
复制标题
DOI：
10.1016/s0145-2126(00)00105-3
复制
发表时间：
2001-03-01
影响因子：
2.7
通讯作者：
Malavasi, F
中科院分区：
文献类型：
--
作者：
Deaglio, S;Canella, D;Malavasi, F
低剂量As 2 O3暴露于RPMI 8226、Karpas 707和U266人骨髓瘤样细胞系后，淋巴因子激活的杀伤细胞（LAK）介导的杀伤作用显著增加，并上调了参与细胞-细胞相互作用的两种分子CD 38和CD 54。此外：同时暴露的效应和目标的As 2 O3产生最有效的条件裂解。LAK细胞对CD 38配体（CD 31）和CD 54配体（CD 11 a）的表达也有上调作用，提示LAK细胞粘附性增强是其杀伤作用增强的原因。使用新鲜分离的骨髓瘤细胞获得了类似的结果。这些发现表明，As（2）O2（3）可能有助于增强免疫系统对抗骨髓瘤。(C)2001爱思唯尔科技有限公司版权所有。
Exposure of RPMI 8226, Karpas 707 and U266 human myeloma-like lines to low doses of As2O3 was followed by a marked increase in lymphokine activated killers (LAK)-mediated killing and up- modulation of CD38 and CD54, two molecules involved in cell-cell interactions. Moreover: simultaneous exposure of effecters and targets to As2O3 yielded the most effective condition for lysis. The expression of CD31 (CD38 ligand) and CD11a (CD54 ligand) was also up-regulated by LAK, suggesting that increased adhesion was responsible for the improved killing. Similar results were obtained using freshly isolated myeloma cells. These findings indicate that As(2)O2(3) may be useful to boost the immune system against myelomas. (C) 2001 Elsevier Science Ltd. All rights reserved.